MAP2K7 and breast carcinoma: Finally, we demonstrated that low expression of MAP2K7 and pJNKT183/Y185 was associated with poor outcomes in early and metastatic ER+ breast cancer patients treated with endocrine therapy and CDK4/6 inhibition.